CEO, Jakob Lindberg, will attend the Nordic Life Science Days, 14-15 September 2016 in Stockholm Sweden.
Oncopeptides presented clinical results from a Phase 2 study of melflufen and dexamethasone in patients with relapsed-refractory multiple myeloma at the 21th European Hematology Association Congress in Copenhagen, Denmark, June 7 – 11.
The results can be downloaded below.
The results further support Oncopeptides’ belief that melflufen has the potential to make a meaningful difference in the lives of patients with relapsed-refractory multiple myeloma, providing a reliable go-to alternative even when conventional therapies have failed”.
For further information or to arrange a meeting for discussions please contact Jakob Lindberg (CEO) or Björn Hammarberg (BD).